Insider

Abbott Laboratories

ABT Health Care · 3 analyses

Abbott Laboratories reported $13B in revenue (+14.5% YoY), compared with a +7.2% median across covered Health Care peers. 1 insider sale recorded.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

What changed

Abbott: net income fell 44% in third-quarter 2026

Abbott Laboratories reported third-quarter 2026 revenue of $13.0 billion, up 14.5% year-over-year. Amid rising operating expenses and the integration of Exact Sciences, acquired in March 2026, Abbott’s net income fell 44% to $920 million.

· Abbott Laboratories

Company history

October 2026

ABBOTT LABORATORIES: 12 recorded developments from 4 official sources in 2026-10.

  • 2026-10-21: Abbott filed a news release announcing that it plans to separate its global nutrition business into an independent, publicly traded company. Source
  • 2026-10-21: Abbott expects to incur one-time charges related to the transaction before the separation, to be quantified at a later date; the Nutrition business will continue to operate as part of Abbott throughout the process. Source
  • 2026-10-21: After the separation Abbott will have sales of approximately $42 billion and about 106,000 employees. Source
  • 2026-10-21: Goldman Sachs & Co. LLC is serving as financial advisor and Wachtell, Lipton, Rosen & Katz as legal counsel to Abbott. Source
  • 2026-10-21: On October 21, 2026, Abbott Laboratories announced its results of operations for the third quarter 2026, furnishing the news release as Exhibit 99.1. Source
  • 2026-10-21: Abbott projects full-year 2026 comparable sales growth of approximately 6.0 percent and tightened its 2026 adjusted diluted EPS guidance range to $5.50 to $5.55, reaffirming the midpoint. Source
  • 2026-10-21: In September Abbott announced FDA approval for its TactiFlex Duo ablation catheter and launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test. Source
  • 2026-10-21: Abbott intends to separate the Nutrition business through a distribution of its shares to Abbott shareholders, who will then own shares in both companies; the transaction is intended to be tax-free for U.S. federal income tax purposes. Source
  • 2026-10-21: Abbott expects to complete the transaction by the end of 2027, subject to regulatory approvals, an effective Form 10 registration statement and final approval by the Abbott Board. Source
  • 2026-10-21: The Nutrition company will have about 16,000 employees and 14 manufacturing sites, with brands including Similac, PediaSure, Pedialyte, Glucerna and Ensure. Source
  • 2026-10-21: Daniel Salvadori, executive vice president and group president, Established Pharmaceuticals and Nutritional Products, will become chief executive officer of the new Nutrition company. Source
  • 2026-10-21: CEO Robert B. Ford says the separation will benefit both companies, setting each up for maximum success in its market. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed November 4, 2026. SEC

LatestEarlierChange
Revenue quarter$13B$11.4B+14.5%
Operating income quarter$1.4B$2.1B-34.0%
Net income quarter$920M$1.6B-44.0%
Diluted EPS quarter$0.53$0.94-43.6%
Dividends per share quarter$0.63$0.59+6.8%
Operating cash flow year to date$5.5B$6.3B-11.4%
Cash and cash equivalents balance$4.1B$8.5B-52.5%
Long-term debt balance$29.5B$9.9B+197.6%

Next results expected around February 3, 2027 (estimate: the quarter ending about December 30, 2026 plus the 35 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Abbott Laboratories ABT$13B+14.5%10.4%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
November 16, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 5, 2026Mary K MorelandSale notice filed3,500$116.00$406,000SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock151,666,065$14,989,157,224-0.6%Q3 2026
State Street81,431,110$8,047,836,601+0.6%Q3 2026
Capital Research Global Investors44,980,846$4,445,523,747+21.9%Q3 2026
Geode Capital Management39,587,887$3,894,300,713+0.9%Q3 2026
Norges Bank (Norway's sovereign fund)23,354,911$2,119,224,624—Q2 2026
Fidelity (FMR)14,403,368$1,423,484,868+7.3%Q3 2026
Two Sigma Investments5,005,388$494,682,496-38.4%Q3 2026
Wellington Management4,651,088$459,667,027-44.0%Q3 2026
Millennium Management2,096,054$207,153,017-41.8%Q3 2026
Citadel Advisors1,699,017$167,913,850-80.2%Q3 2026
Renaissance Technologies458,466$45,310,195-33.2%Q3 2026
D. E. Shaw & Co.363,307$35,905,630-75.1%Q3 2026
Bridgewater Associates55,789$5,513,627-6.7%Q3 2026
Soros Fund Management44,750$4,422,6430.0%Q3 2026
T. Rowe Price23,546,479$2,327,100+3.3%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.